Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €46.67 EUR
Change Today +0.48 / 1.04%
Volume 1.0K
As of 3:08 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - €72.68
52 Week Low
10/13/14 - €27.79
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

isis pharmaceuticals inc (ISI) Related Businessweek News

View More BusinessWeek News

isis pharmaceuticals inc (ISI) Details

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, which include neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., OncoGenex Technologies Inc., Janssen Biotech, Inc., and Atlantic Pharmaceuticals Limited. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

390 Employees
Last Reported Date: 03/2/15
Founded in 1989

isis pharmaceuticals inc (ISI) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $1.5M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $584.6K
Chief Operating Officer, Director and Member ...
Total Annual Compensation: $1.1M
Senior Vice President of Development
Total Annual Compensation: $636.1K
Senior Vice President of Antisense Research
Total Annual Compensation: $631.6K
Compensation as of Fiscal Year 2014.

isis pharmaceuticals inc (ISI) Key Developments

Isis Pharmaceuticals, Inc. Revised Earnings Guidance for the Full Year 2015

Isis Pharmaceuticals, Inc. revised earnings guidance for the full year 2015. Because of strong financial performance in the first half of 2015, the company expects to substantially improve upon year-end guidance. The company is reducing projected pro forma NOL by more than 40% to a pro forma NOL in the low $30 million range. The company also projecting to end the year with more than $750 million in cash, which is an increase over original cash guidance of more than $120 million and a modest increase over 2014 year end cash balance. The revised guidance also reflects the many opportunities have to generate revenue and cash throughout the second half of 2015.

Isis Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Isis Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenue was $120.4 million compared to $57.1 million for the same period in 2014. Net income of $35.6 million compared to a net loss of $12.1 million for the same periods in 2014. Diluted net income per share was $0.29 compared to a diluted net loss of $0.10 for the same period in 2014. Income from operations was $44,646,000 against loss from operations of $6,650,000 a year ago. For the six months, revenue was $183.0 million compared to $85.2 million for the same period in 2014. Net income of $18.9 million compared to a net loss of $43.4 million for the same period in 2014. Diluted net income per share $0.15, compared to a diluted net loss of $0.37 for the same period a year ago. Income from operations was $35,317,000 against loss from operations of $36,317,000 a year ago.

Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia

Isis Pharmaceuticals Inc. announced that the FOCUS FH phase 3 study of KYNAMRO® (mipomersen sodium) in patients with severe heterozygous familial hypercholesterolemia (severe HeFH) met its primary efficacy endpoint, a statistically significant reduction in LDL-cholesterol after 60 weeks of treatment of once weekly injections of 200 mg of KYNAMRO compared to placebo. LDL-cholesterol reduction was similar to that observed in previous phase 3 studies. In addition, based on the data available for review, the safety profile of KYNAMRO observed in the FOCUS FH trial was similar to the safety profile reported in previous phase 3 studies. Genzyme will provide a more in depth review of the safety and efficacy data at a future medical meeting.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISI:GR €46.67 EUR +0.48

ISI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $39.46 USD +0.33
Acorda Therapeutics Inc $31.71 USD -0.15
Alnylam Pharmaceuticals Inc $97.80 USD +0.55
Depomed Inc $26.66 USD +0.04
Sarepta Therapeutics Inc $33.81 USD +0.28
View Industry Companies

Industry Analysis


Industry Average

Valuation ISI Industry Range
Price/Earnings 100.0x
Price/Sales 19.9x
Price/Book 20.7x
Price/Cash Flow 266.3x
TEV/Sales 15.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at